ReviewCureus2025
Sepsis-induced Atrial Fibrillation: Can We Predict and Prevent This High-Risk Complication?
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Aspirin is associated with improved outcomes in sepsis patients with atrial fibrillation: an analysis of the MIMIC-IV and eICU-CRD databases.Frontiers in cardiovascular medicine · 2026Article
- Treatment of supraventricular arrhythmias in critical care patients with sepsis.Frontiers in cardiovascular medicine · 2026Review
- Toward ED Based Cardio Oncology Pathways From a Nationwide Arrhythmia Cohort.Journal of arrhythmia · 2025Article
- Development and Validation of a Risk Prediction Model for New-Onset Atrial Fibrillation in Sepsis.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-induced new-onset atrial fibrillation (NOAF) is a frequent and serious complication in critically ill patients, linked to increased morbidity, mortality, stroke, and prolonged hospitalization. Though often transient during acute illness, NOAF is now recognized as a predictor of long-term cardiovascular vulnerability, with recurrence rates exceeding 50% over five years and a significantly heightened risk of thromboembolic events. Stroke risk is notably elevated in this population, yet the role of anticoagulation remains uncertain due to potential bleeding complications and lack of clear guidelines. This review consolidates current evidence on the pathophysiology, incidence, risk factors, and clinical impact of sepsis-induced NOAF, with a focus on stroke prevention, recurrence, anticoagulation challenges, and emerging predictive models. Additionally, it examines prevention strategies that target inflammatory and hemodynamic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.